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Lots of things are mysteries.
But that doesn’t mean there isn’t an answer to them.
It’s just that scientists haven’t found the answer yet.

— Mark Haddon
“A Curious Incident of the Dog in the Nighttime”
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ABSTRACT
Notch-1 is a cell fate regulatory protein and a potent breast oncogene. Notch-1
and its ligand Jagged-1 are over-expressed in human breast cancers that are associated
with poor overall survival (Reedijk, Odorcic et al. 2005). Deregulated Notch signaling
may contribute to tumorigenesis by increasing proliferation, inhibiting differentiation,
and preventing apoptosis (Miele, Golde et al. 2006). The mitogen-activated protein
kinase (MAPK) pathway is a critical cell signaling pathway that has been implicated in
the development and progression of cancer (Hanahan and Weinberg 2000). Four major
MAPK pathways are involved in both cell growth and apoptosis. The regulation of these
pathways is critical for cell fate decisions (Boutros, Chevet et al. 2008). One of the major
MAPK subfamilies is the Extracellular Signal Regulated Kinases 1/2 (ERK ½, or
p44/p42) signaling cascade. Hyper-activated ERK1/2 has been implicated in a large
subset of mammary tumors and low ERK1/2 activity in primary breast tumors correlates
with longer relapse-free survival (Mueller, Flury et al. 2000). Activation of ERK1/2
results in signals that stimulate proliferation (Pearson, Robinson et al. 2001),
differentiation (Pearson, Robinson et al. 2001), survival (Pearson, Robinson et al. 2001),
angiogenesis (Pages, Milanini et al. 2000), motility (Joslin, Opresko et al. 2007), and
invasion (Price, Avraham et al. 2002); all of which contribute to breast cancer
progression.

xiii

The overall objective of this thesis is to identify a novel crosstalk between Notch1 and ERK1/2 signaling and to understand the mechanism of this crosstalk in breast
cancer. The hypothesis of this project is: Notch-1 specifically activates ERK1/2 in
multiple breast cancer subtypes through Aim 1A. Inhibition of MKP-1, a negative
regulator of ERK1/2; Aim 1B. Activation of a receptor tyrosine kinase; Aim 2.
Upregulation of MEK1/2, the activating kinase of ERK.
The first aim defines the crosstalk between Notch-1 and MKP-1. We demonstrate
that Notch-1 downregulates transcription of MKP-1, but upregulates MKP-1 protein
levels, suggesting that Notch-1 regulation of ERK may be downstream of MKP-1.
Additionally, the first aim defines Notch crosstalk with receptor tyrosine kinases (RTKs)
in MCF-7 and BT474 breast cancer cells. In a cell line with high ERK1/2 activity (MCF7), the vascular endothelial growth factor receptor 3 (VEGFR3) was highly
phosphorylated. Activity of VEGFR3 was abrogated upon Notch-1 inhibition, which
correlated with a decrease in ERK activity. BT474 sensitive cells, which have low ERK
activity, also had low VEGFR3 phosphorylation, which was not affected by Notch-1.
The differences in VEGFR3 activity may account for the varying levels of ERK
phosphorylation among cell lines, but Notch-1 activation of ERK is most probably not
through activation of an RTK. In the second aim, overexpression of Notch-1 induced
ERK phosphorylation and this effect was abrogated by inhibition of MEK. Inhibiting the
proteasome caused a significant increase in ERK phosphorylation and Notch-1 protein,
indicating that Notch-1 stabilization may be critical for ERK activation. Taken together,
these results suggest that Notch-1 is activating ERK1/2 in multiple subsets of breast
cancer. This novel crosstalk may be regulated by stabilization of Notch-1 protein, which
xiv

appears to involve MEK1/2 or ERK1/2 activity.

Future investigations will aim to

determine the exact mechanism of Notch-1 activation of ERK and the role of MEK or
ERK in Notch-1 stabilization.

xv

CHAPTER ONE
INTRODUCTION
Breast Cancer.
Breast cancer is the most frequently diagnosed cancer among women worldwide.
In the United States, 1 in 8 women will develop breast cancer over the course of her
lifetime. Among women in the United States, breast cancer is the second leading cause
of cancer-related deaths and is the leading cause of cancer-related deaths among women
worldwide (American Cancer Society 2010). Breast cancers can generally be divided
into five subtypes of disease, which are related to mammary epithelial biology and
molecular classification: luminal A, luminal B, Her2/Neu or ErbB-2-overexpressing,
basal-like or triple negative, and normal breast-like. Luminal A and luminal B breast
cancers comprise approximately 70% of all breast cancers and are characterized by high
expression of the estrogen receptor α (ERα) and progesterone receptors A and B (PR).
Luminal A and luminal B subtypes are distinguished by their ErbB-2 status: The luminal
A subtype is ErbB-2-nonoverexpressing (ErbB-2-/low), while the luminal B subtype is
ErbB-2-overexpressing (ErbB-2+) (Sotiriou et al., 2003). The Her2/Neu or ErbB-2+
subtype represents 15% to 25% of breast cancers and is designated as negative for ER/PR
expression, but contains the ErbB-2 gene amplification (Sotiriou and Pusztai 2009). The
fourth subtype, the triple negative or basal-like subtype, presents approximately 15% of
breast cancers and lacks expression of ER/PR and ErbB-2 proteins. The fifth subtype is
1

2
the normal-like breast cancer, which resembles normal mammary epithelial cells and
expresses genes associated with adipose tissue. The subtypes are summarized in Table
1-1.

3

Subtype

Molecular Classification

Prevalence

Luminal A

ER+, PR+, ErbB-2-

Luminal B

ER+, PR+, ErbB-2+

Her2/Neu or ErbB-2+

ER-, PR-, ErbB-2+

15-25%

Triple Negative

ER-, PR-, ErbB-2-

~ 15%

Normal-like

Adipose-associated genes

~ 70%

Table 1-1. Molecular classification of the five major breast cancer subtypes. Breast
cancers can generally be divided into five subtypes of disease, which are related to
mammary epithelial biology and molecular classification: luminal A, luminal B,
Her2/Neu or ErbB-2-overexpressing, basal-like or triple negative, and normal breast-like.
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Estrogen Receptor α.
Estrogen receptor α (ERα) is a nuclear steroid hormone receptor that functions as
a DNA-binding transcription factor that regulates gene expression within the nucleus.
The binding of 17β-estradiol (E2) to its cognate receptor, ERα, activates or represses
genes involved in the regulation of proliferation and differentiation of normal mammary
cells (Clarke, Liu et al. 2003).

17β-estradiol is a lipophilic, steroid hormone that

traverses the phospholipid bilayer of the plasma membrane. As a result, ERα does not
need to be membrane-bound in order to become activated by 17β-estradiol (Levin 2005).
Both 17β-estradiol alone and 17β-estradiol bound to ERα (E2-ERα) are implicated in the
development of breast cancer (Yue, Wang et al. 2005). Two hypotheses aim to explain
this relationship.

The first hypothesis states that binding of 17β-estradiol to ERα

stimulates proliferation of mammary cells, increasing cell division and DNA replication,
thus elevating the risk for replication errors over a lifetime (Levin 2005).

The

accumulation of these errors could result in mutations that disrupt normal cellular
processes, including DNA damage repair and apoptosis. The second hypothesis states
that since 17β-estradiol metabolism leads to the production of genotoxic by-products,
DNA damage is more likely in a system where 17β-estradiol is present (Yue, Wang et al.
2005).
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Estrogen Receptor Signaling Pathways.
The estrogen receptor-α (ERα) can induce cellular changes through several
different molecular mechanisms (Figure 1-1): 1. Classical ligand-dependent; 2. Ligandindepenedent; 3. ERE binding-independent; 4. Nongenomic.
In the “classical” or ligand-dependent signaling pathway, ERα requires ligand
binding in order to induce an activating conformational change (Figure 1-1, Pathway 1).
The active conformation then allows for homodimerization and binding to DNA response
elements called estrogen response elements (EREs). Binding of E2-ERα to cofactor
proteins will then exert either a positive or negative effect on expression of the
downstream target genes (McKenna et al., 1999).
The second signaling pathway is ligand-independent and involves ERα crosstalk
with growth factor receptors (Figure 1-1, Pathway 2). Epidermal growth factor receptor
(EGFR) and insulin-like growth factor-1 receptor (IGF-1R) are known to activate ERα
and increase the expression of ERα target genes (Smith 1998). While, the exact pathway
of ERα and growth factor receptor crosstalk is unclear, evidence indicates that changes in
the phosphorylation state of ERα by cellular kinases, including those of the mitogenactivated protein kinase (MAPK) cascade, may be an important mechanism of the ligandindependent pathway (Kato 2001).
The ERE binding-independent pathway requires that ERα be bound to ligand,
however the ligand-activated ERα dimers do not bind EREs. Evidence demonstrates that
the 17β-estradiol-ERα complex (E2-ERα) utilizes the activating function domains (AF-1
and AF-2) of ERα to bind directly to AP-1 transcription factor mediating transcription of
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AP-1-directed genes (Kushner, Agard et al. 2000) (Figure 1-1, Pathway 3). This pathway
provides an explanation for ERα regulation of genes in which a functional ERE cannot
be documented.
The fourth and final pathway of ERα signaling is the nongenomic signaling
mechanism (Figure 1-1, Pathway 4).

Initial evidence suggested that a nongenomic

signaling mechanism may account for the rapid biological effects of 17β-estradiol in a
variety of human tissues. Data supporting the nongenomic role of the ERα suggests that
E2-ERα activates MAPK (Mendelsohn 2000) and phosphatidylinositol 3-kinase (PI-3K)
pathways within minutes (Simoncini, Hafezi-Moghadam et al. 2000).

Clinical Therapies Used to Treat Estrogen Receptor-Positive Breast Cancer.
Selective ERα modulators (SERMs), such as tamoxifen or raloxifene, are
compounds that exhibit tissue-specific estrogenic activity.

Tamoxifen is an ERα

antagonist that has been FDA approved for the treatment of ERα-positive breast cancers
since 1978. Tamoxifen exerts its effects by competitively binding ERα and blocking
17β-estradiol-stimulated growth (Arpino, Green et al. 2004) and has been shown to
reduce disease recurrence and mortality in 50% of patients with ERα+ breast cancers
(2005). The estrogenic activity of SERMs, however, has been shown to exert differential
effects on 17β-estradiol-responsive genes.

In contrast, ICI 182,780 (ICI) is a pure

antiestrogen shown to be a potent and specific competitive inhibitor of 17β-estradiol
action (Wakeling 1991). Aromatase inhibitors (AIs) have also been developed for the
treatment of ERα+ breast cancers. AIs inhibit the activity of aromatase, the critical

7
enzyme responsible for synthesizing 17β-estradiol from the androgen, androstenedione in
postmenopausal women (Howell 2005). In pre-menopausal women, AIs are not an
effective treatment for ERα+ breast cancers because they are unable to inhibit the very
high concentrations of 17β-estradiol that are produced by the ovaries (Goss, Ingle et al.
2003).

8

Figure 1-1. Estrogen receptor α exerts downstream effects through four pathways:
1. Classical, in which the estrogen receptor (ER) binds its ligand, 17β-estradiol (E2),
dimerizes, and binds an estrogen response element (ERE) to activate transcription of
target genes; 2. Ligand-independent, in which a receptor tyrosine kinase at the membrane
is activated by a growth factor (GF), thus activating a phosphorylation cascade. Once the
ER dimer is phosphorylated, it can bind the ERE and activate transcription; 3. ERE
binding-independent, which requires binding to 17β-estradiol and ER dimerization, but
the dimer activates transcription of AP-1 genes, with the cooperation of Jun/Fos
transcription factors; 4. Nongenomic, in which 17β-estradiol enters the cell and activates
intracellular signaling cascades independent of DNA binding.
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ErbB Family of Receptors
The ErbB family of receptors is comprised of four distinct receptors: Epidermal
growth factor receptor (EGFR) (also known as ErbB-1 or Her1); ErbB-2 (Her2), ErbB-3
(Her3) and ErbB-4 (Her4).

Generally, the ErbB receptors are comprised of an

extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic
tyrosine kinase-containing domain (Olayioye, Neve et al. 2000). Specifically, EGFR,
ErbB-3 and ErbB-4 contain the N-terminal, extracellular ligand-binding domain while
EGFR, ErbB-2 and ErbB-4 contain the C-terminal, intracellular tyrosine kinase domain
(Figure 1-2). The ErbB receptors are activated by binding to growth factors of the EGFfamily that include epidermal growth factor (EGF), tumor growth factor-α (TFGα),
amphiregulin (AREG), and heregulin1-4 (HRG) (Yang, Liu et al. 2006; Revillion,
Lhotellier et al. 2008).
ErbB-2 is a potent oncoprotein (Yarden and Sliwkowski 2001) and is
overexpressed in 15-25% of breast cancers (Morris, and Carey, L.A., 2006). ErbB-2positive breast cancer is highly proliferative and aggressive (Slamon, Clark et al. 1987)
and confers poor prognosis with higher mortality rates (Morris and Carey 2006). ErbB-2
is a type I transmembrane receptor tyrosine kinase (RTK) that lacks the ability to bind
ligand extracellularly. ErbB-2 can be activated in a ligand-dependent manner by heterodimerization with ligand-bound EGFR, ErbB-3 or ErbB-4 (Knowlden, Hutcheson et al.
2003) or in a ligand-independent manner by homo-dimerization (Worthylake, Opresko et
al. 1999). Activation of ErbB-2 is associated with activation of MAPK and PI-3K, which
stimulate cell survival and cell cycle progression (Price, Avraham et al. 2002) as well as

10
the AKT pathway, which stimulates angiogenesis and metastasis (Niu and Carter 2007).
Additionally, activation of ErbB-2 stimulates cell division, migration and anti-apoptosis,
all of which are associated with tumorigenesis (Daub, Weiss et al. 1996).

ErbB Signaling Pathways.
Evidence suggests that ErbB-2 is the preferred heterodimerization partner of the
other ErbB family members (Tzahar, Waterman et al. 1996). Growth factors that bind
EGFR,

ErbB-3

or

ErbB-4

initiate

receptor

heterodimerization,

leading

to

autophosphorylation of C-terminal tyrosine residues (Weiss and Schlessinger 1998). Src
homology 2 (SH2) domain-containing cellular adaptor proteins, such as Shc, Grb2, or
p85, the regulatory subunit of PI-3K, bind the phosphorylated tyrosine residues and
transmit signals to the MAPK cascade or PI-3K-AKT-mTOR cascade to promote cell
proliferation and survival (Janes, Daly et al. 1994). In addition to the SH2 domain, Grb2
also contains an SH3 domain, which binds to proline-rich domain-containing proteins,
such as son of sevenless (SOS) (Lowenstein, Daly et al. 1992). SOS is a key regulator of
Ras, which activates the MAPK (ERK1/2) cascade, which promotes cell cycle
progression (Treinies, Paterson et al. 1999), cell proliferation (Boutros, Chevet et al.
2008) and DNA synthesis (Graves, Guy et al. 2000) (Figure 1-3).

Clinical Therapies Used to Treat ErbB-2-Positive Breast Cancer.
Trastuzumab (Herceptin®) is a humanized, monoclonal antibody that directly
targets the extracellular juxta-domain of ErbB-2 (Yarden and Sliwkowski 2001) and is
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FDA-approved for the treatment of all ErbB-2+ breast cancers. Trastuzumab is clinically
used for the treatment of ErbB-2+ metastatic disease (Yarden and Sliwkowski 2001), but
more recent clinical trials suggest a benefit for trastuzamab as an adjuvant therapy for
women with less advanced ErbB-2+ breast cancer (Dahabreh, Linardou et al. 2008;
Jahanzeb 2008; Mackey, McLeod et al. 2009; Mariani, Fasolo et al. 2009). Trastuzumab
inhibits ErbB-2 signaling by binding to the extracellular domain of ErbB-2 to prevent
homo- or heterodimerization of the receptor. This action promotes the degradation of
ErbB-2, thus abrogating signal transduction and inhibiting proliferation and survival of
breast cancer cells (Baselga and Albanell 2001; Nagata, Lan et al. 2004).
Resistance to trastuzamab remains a major problem in the treatment of ErbB-2+
metastatic breast cancers. Trastuzumab is only effective as a single agent in 26% to 40%
of women with ErbB-2-overexpressing breast cancers (Vogel, Cobleigh et al. 2002).
Combining trastuzumab with cytotoxic chemotherapy agents such as anthracyclines
(Slamon, Clark et al. 1987) or taxanes (Seidman, Fornier et al. 2001) has been shown to
increase the overall response rate to as high as 60% (Burstein, Harris et al. 2003).
However, the combination of trastuzumab with chemotherapeutic agents increases the
risk for developing cardiac dysfunction (Slamon, Clark et al. 1987).
Lapatinib is a recent anti-ErbB-2 agent and that has recently been approved for
the treatment of ErbB-2+ breast cancer that is resistance to trastuzumab. Lapatinib is a
dual EGFR/ErbB-2 tyrosine kinase inhibitor (TKI) (Romond, Perez et al. 2005) that
selectively targets and inhibits the EGFR and ErbB-2 tyrosine kinase domains (Konecny,
Pegram et al. 2006). Lapatinib is able to induce apoptosis in breast cancer cell lines that
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are resistant to trastuzamab (Nahta, Yuan et al. 2007). However, resistance to lapatinib
also occurs in vitro (Xia, Bacus et al. 2006).

13

Figure 1-2. ErbB receptors homo- and heterodimerize to activate downstream
signaling. EGFR (ErbB-1) and ErbB-4 contain an extracellular ligand binding domain as
well as an intracellular tyrosine kinase domain. As a result, EGFR and ErbB-4 can both
homo- and heterodimerize in order to activate downstream signaling. ErbB-2 contains
the intracellular tyrosine kinase domain, but lacks the extracellular ligand binding domain
and therefore, must heterodimerize with EGFR, ErbB-3 or ErbB-4 in order to activate
downstream signaling in a ligand-dependent manner.
However, ErbB-2 can
homodimerize and autophosphorylate the activating tyrosine residues to activate
signaling. ErbB-3 contains the extracellular ligand binding domain, but lacks the
intracellular tyrosine kinase domain and therefore, must heterodimerize with EGFR,
ErbB-2 or ErbB-4 to exert downstream effects.
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Figure 1-3. Upon dimerization, the ErbB receptors are phosphorylated on tyrosines
within the intracellular domain. Effector proteins such as Shc and Grb contain SH2
domains, which allow them to bind the phosphorylated tyrosine resides of the receptor
tyrosine kinases such as ErbB receptors. Grb2 also contains an SH3 domain which
allows it to bind other effector proteins in order to propagate a downstream signaling
effect. Other pathways activated by the ErbB family of receptors include PI3K-AKT,
Nck-Jnk, and PLC-PKC.
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Notch Receptor
The Notch signal transduction pathway is a highly evolutionarily conserved
family of transmembrane ligands and receptors. Notch signaling regulates important cell
fate decisions, including differentiation, proliferation, and apoptosis (Dievart, Beaulieu et
al. 1999). Notch receptor and ligand interactions regulate cell fate decisions during cellto-cell contact (Artavanis-Tsakonas, Rand et al. 1999; Miele, Golde et al. 2006). There
are four Notch receptors, Notch-1 through Notch-4, and five Notch ligands: Delta like-1
(DLL-1), Delta like-2 (DLL-2), Delta like-3 (DLL-3), Jagged-1 (JAG-1), and Jagged-2
(JAG-2).

Expression of constitutively active forms of Notch-1 or Notch-4 causes

mammary tumors in mice (Jhappan, Gallahan et al. 1992; Dievart, Beaulieu et al. 1999;
Miele, Golde et al. 2006) and activation of Notch-1, Notch-3 or Notch-4 in mouse
mammary epithelial cells leads to the development of mammary tumors (Jhappan,
Gallahan et al. 1992; Hu, Dievart et al. 2006). Additionally, Notch-1 and its ligand
Jagged-1 are overexpressed in human breast cancers that are associated with the poorest
overall survival (Reedijk, Odorcic et al. 2005).

Notch Processing and Signaling
Notch proteins are derived from large polypeptide precursors.

The Notch

precursor protein must undergo several cleavages necessary for maturation and activation
(Figure 1-4). The first cleavage by a furin-like protease (Logeat, Bessia et al. 1998)
occurs in the trans-Golgi apparatus and is followed by delivery of the heterodimeric form
of Notch to the cell membrane (Blaumueller, Qi et al. 1997). This cleavage, denoted as
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S1, results in the mature Notch receptor. Mature Notch receptors are heterodimers of a
180 kDa fragment that comprises the extracellular domain of the protein (NEC) and a 120
kDa, membrane-tethered intracellular portion (NIC) containing a short transmembrane
subunit (NTM) (Figure 1-5). NEC is non-covalently associated with NTM via cationic
(Ca+2 or Mg+2) electrostatic interactions that are dependent on the Ca2+-binding LN
repeats located in the NEC (Rand, Grimm et al. 2000).
The full-length heterodimeric form of Notch (NFL) contains several domains
(Figure 1-5). NEC contains several EGF-like repeats that participate in ligand binding
and three copies of a Lin/Notch (LN) conserved sequence proximal to the transmembrane
region. The intracellular portion of Notch (NIC) contains four distinct domains: a RAM
domain, six ankryin repeats, a transcriptional activation domain (TAD) (with the
exception of Notch-3 and -4), and a proline-, glutamate-, serine- and threonine-rich
sequence (PEST).

On either side of the ankryin repeats are nuclear localization

sequences (NLS) (Jeffries and Capobianco 2000).
Extracellular binding of Notch receptor to membrane-bound Notch ligand on a
neighboring cell or on the same cell causes the NEC and NTM to dissociate. Dissociated
NEC is endocytosed into the ligand-expressing cell and dissociation triggers two
subsequent proteolytic cleavages of NTM. The first cleavage is catalyzed by TNF-alpha
converting enzyme (TACE), a metalloprotease of the a disintegrin and metalloprotease
(ADAM) family (Brou, Logeat et al. 2000; Mumm, Schroeter et al. 2000). The resulting
Notch is a membrane-tethered form of NIC containing the full transmembrane region and
intracellular domain. This form of Notch is short-lived and serves as the substrate for the
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third and final cleavage (S3) of Notch (Saxena, Schroeter et al. 2001). The S3 cleavage
event is catalyzed by the γ-secretase complex, which is comprised partly of Presenilin 1
and 2 and Nicastrin (Kimberly, LaVoie et al. 2003). The complex enzyme is an aspartic
protease that catalyzes the cleavage within the Notch transmembrane domain, resulting in
the release of the Notch intracellular domain (NIC) (Mizutani, Taniguchi et al. 2001).
NIC can then translocate to the nucleus where it activates transcription via
binding to CBF-1 (Mumm and Kopan 2000) and formation of a co-activator complex,
which includes Mastermind (MAML) (Figure 1-6) (Artavanis-Tsakonas, Rand et al.
1999; Nickoloff, Osborne et al. 2003; Lai 2004). The release of NIC can be inhibited by
the use of γ-secretase inhibitors (GSIs), which inhibit the third and final cleavage step of
Notch activation. GSIs are currently in clinical trials for the treatment of breast cancers
and other solid tumors (Al-Hussaini, Subramanyam et al.).
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Figure 1-4. Full-length Notch undergoes three separate cleavage events to become
activated. The full-length Notch receptor contains multiple domains that allow for
various activities including ligand binding and transcriptional activation (described in
detail in Figure 1-5). In order to become the mature Notch protein, Notch-1 must
undergo three cleavage events (S1 through S3). S1 is catalyzed by a furin-like convertase
and occurs in the trans-Golgi, resulting in the Notch extracellular domain (NEC) and
Notch transmembrane domain (NTM). Following the S2 cleavage event, catalyzed by a
disintigrin, the Notch receptor contains an intracellular domain (NIC) in addition to the
NEC and NTM. The third and final cleavage is catalyzed by gamma-secretase and
results in the release of the NIC domain, which can then translocate into the nucleus to
activate transcription of target genes.
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Figure 1-5. Full-length Notch protein and its domains. The full-length heterodimeric
form of Notch (NFL) contains several domains. NEC contains several EGF-like repeats,
the highlighted of which are thought to participate in ligand binding. Proximal to the
transmembrane region are three copies of a Lin/Notch (LN) conserved sequence, which
maintain the association between the polypeptides resulting from the S1 cleavage. The
intracellular portion of Notch (NIC) contains four distinct domains: a RAM domain, six
ankryin repeats, a transcriptional activation domain (TAD) (with the exception of Notch3 and -4), and a proline-, glutamate-, serine- and threonine-rich sequence (PEST). On
either side of the ankryin repeats are nuclear localization sequences (NLS), which
promote the translocation of NIC into the nucleus following S3 cleavage.
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Figure 1-6. Notch-1 signaling requires ligand binding, release of the NIC domain
and translocation into the nucleus. Following the S1 cleavage event, the mature Notch
receptor is shuttled to the cell membrane where it can bind ligand on a ligand-expressing
cell. Following ligand binding, the TACE enzyme catalyzes the S2 cleavage event and
the bound ligand and NEC are endocytosed into the ligand-expressing cell, which allows
for the S3 cleavage. NIC is released and, once inside the nucleus, can bind the CBF-1
family of transcription factors, replacing a co-repressor complex with co-activators, thus
activating transcription of Notch target genes.
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MAP Kinases.
Mitogen-activated protein kinases (MAPKs) are important signal transducing
enzymes that are involved in many facets of cellular regulation, including cell survival
and adaptation.

There are four major MAPK families that are distinctly regulated

through three-tiered signaling cascades (Figure 1-7): extracellular signal-related kinase
(ERK) 1/2, Jun amino-terminal kinase (JNK), p38 protein, and ERK5. ERK signaling is
activated by growth factors and is generally involved in stimulating growth (Boutros,
Chevet et al. 2008). ERK1/2 promotes cell proliferation by stimulating DNA synthesis
through phosphorylation of carbamoyl phosphate synthetase II, one of the rate-limiting
enzymes involved in pyrimidine nucleotide biosynthesis (Graves, Guy et al. 2000).
Additionally, ERK promotes cell-cycle progression by phosphorylating transcription
factors that upregulate the transcription of critical cell cycle genes, such as cyclin D1
(Treinies, Paterson et al. 1999), cyclin A (Boutros, Chevet et al. 2008) and cyclin E
(McCubrey, Steelman et al. 2006).

MAPK Signaling Pathways.
MAP kinase signaling cascades (MAPK cascades) each consist of three main
enzymes: a MAP kinase, MAP kinase kinase (MKK, MEK or MAP2K) and MAP kinase
kinase kinase (MKKK, MEKK, or MAP3K) that are activated in series (Chang and Karin
2001). Generally, an extracellular stimulus activates a MAP3K, which phosphorylates a
MAP2K on serine and threonine residues, thus activating it. Once active, the MAP2K
will activate a MAP kinase by phosphorylating target threonine and tyrosine residues
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(Chang and Karin 2001). Active MAP kinases are serine/threonine protein kinases that
can then regulate various cellular activities, including proliferation, differentiation, and
cell survival (Pearson, Robinson et al. 2001).
There are four major MAPK signaling cascades (ERK1/2, JNK, p38, ERK 5) that
are activated by various extracellular stimuli and exert differing effects within the cell
(Weston, Lambright et al. 2002). The ERK1/2 cascade is preferentially activated by
growth factors and stimulates proliferation, differentiation, and survival (Figure 1-8)
(Yoon and Seger 2006). The c-Jun N-terminal kinases (JNKs), also known as stressactivated protein kinases (SAPKs), and p38 kinases are activated in response to stress
stimuli, such as cytokines, ultraviolet radiation and heat shock (Ip and Davis 1998). The
JNK and p38 cascades promote apoptosis, cell differentiation and proteasome
degradation of target proteins (Boutros, Chevet et al. 2008). The ERK5 cascade is
activated by both stress stimuli and growth factors (Kant, Schumacher et al. 2006) and
promotes angiogenesis, cell proliferation and cell cycle arrest (Yoon and Seger 2006).

MAPK Phosphatases.
MAP kinases are dephosphorylated and thus, the extent of their activity is
controlled by mitogen-activated protein kinase phosphatases (MKPs). MKPs are also
known

as

dual

specificity

phosphatases

(DUSPs)

and

inactivate

ERK

by

dephosphorylating both tyrosine and threonine residues (Wu 2007). Recently, growing
evidence has suggested a role for MKPs in chemoresistance in a variety of cancers
(McCubrey, Steelman et al. 2006), including breast, lung, prostate, ovarian, pancreatic,
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liver, and gastric cancer (Wu 2007). Specifically, MKP-1 is overexpressed up to 5-fold
or more in a large proportion of breast cancers (Wang, Cheng et al. 2003). Furthermore,
overexpression of MKP-1 suppressed the ability of anthracycline, an alkylating agent, or
doxorubicin to induce programmed cell death in breast cancer cells (Small, Shi et al.
2007). Most recently, data suggests that increased MKP-1 expression may predict poor
prognosis, and be a potential therapeutic target in breast cancer (Rojo, GonzalezNavarrete et al. 2009).
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Figure 1-7. There are four main MAP kinase pathways: ERK1/2, p38, JNK and
ERK5. The four major MAPK cascades are activated by a variety of extracellular
signals including growth factors, mitogens, cytokines, stress factors, or activation of gcoupled protein receptors. Active cacades exert a variety of effects in cells including
growth, differentiation, apoptosis and development. Each cascade consists of a MAP
kinase (ERK1/2, p38, SAPK/JNK, ERK5), MAP kinase kinase (MEK1/2, MKK3/6,
MKK4/7, MEK5), and a MAP kinase kinase kinase (Raf, MLK3, MEKK1/4, MEKK2/3).
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Figure 1-8. The classic activation pathway of ERK1/2. Classically, the ERK1/2
MAPK cascade is activated by receptor tyrosine kinases on the cell membrane. Effector
proteins Shc and GRB2 bind the phosphorylated tyrosines and activate Ras. Ras then
binds Raf and initiates the phosphorylation cascade, activating MEK1/2, which then
activates ERK1/2. MKP-1 is a MAPK phosphatase known to inhibit ERK by
dephosphorylating the activating tyrosine and threonine residues.

CHAPTER TWO
PRELIMINARY DATA, HYPOTHESIS, AND SPECIFIC AIMS
Preliminary Data
The estrogen receptor, ErbB-2 and Notch signaling pathways are prominent
signaling pathways implicated in the development of breast cancer and in resistance to
breast cancer therapies. Recently, important crosstalks between these pathways were
identified, but the mechanisms remain unclear. In one study, it was demonstrated that
ErbB-2 overexpression inhibits Notch-1 activity and that inhibiting Notch-1 re-sensitizes
trastuzumab-resistant ErbB-2-positive breast cancer cells to trastuzumab (Osipo, Patel et
al. 2008). A second study demonstrated that Notch signaling was significantly inhibited
in breast cancer cells treated with 17β-estradiol, indicating an inhibitory role of the
estrogen receptor on Notch (Rizzo, Miao et al. 2008).

Additionally, the study

demonstrated that dual inhibition of Notch and ER caused significant tumor regression in
ER-positive tumors. Based on these reports, we aimed to investigate the mechanism of
the crosstalk between these three important signaling pathways (Rizzo, Miao et al. 2008).
To begin this investigation, we transfected MCF-7 breast cancer cells with either
control or Notch-1 siRNA. Following transfection, we treated the cells with ICI, a pure
antiestrogen, Lapatinib, a tyrosine kinase inhibitor specific to EGFR and ErbB-2, or ICI
plus Lapatinib. Under vehicle conditions (SCBi, Veh), MCF-7 cells have high ERK1/2
phosphorylation, which is decreased upon ICI, Lapatinib and combination treatments
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(Figure 2-1).
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However, when Notch-1 is inhibited by the siRNA (Notch-1i, Veh),

ERK1/2 phosphorylation is greatly decreased and drug treatments have no additive
inhibitory effects.

Furthermore, AKT phosphorylation was not inhibited by Notch-1

inhibition to the same extent as ERK (Figure 2-1).
To investigate whether this effect of Notch-1 inhibition on ERK1/2 was specific
to MCF-7 cells, we performed the same Notch-1 knockdown experiments in four
additional breast cancer cell lines (Table 2-1): SKBr3, BT474 Sensitive to trastuzumab
(BTHS), BT474 Resistant to trastuzumab (BTHR) and MDA-MB-231.

ERK1/2

phosphorylation was decreased by approximately 50% upon Notch-1 inhibition in SKBr3
cells and to a lesser extent in BT474 resistant cells. However, in BT474 sensitive cells,
ERK phosphorylation was nearly undetectable and Notch-1 inhibition had little to no
effect (Figure 2-2).

Additionally, Notch-1 inhibition had no effect on ERK

phosphorylation in MDA-MB-231 cells.
The BT474 cells provide a biologically relevant in vitro model for resistance to
trastuzumab.

Recently, it was demonstrated that Notch-1 plays a critical role in

resistance in the BT474 resistant cells. Furthermore, when we compared the relative
levels of ERK1/2 and AKT activity between BT474 sensitive and resistant cells, we
demonstrated that both AKT and ERK phosphorylation are higher in the resistant cell line
(Figure 2-3). To further investigate the role of Notch-1 and ERK1/2 crosstalk in the
BT474 cells, we asked the question: Is Notch sufficient to activate ERK1/2? To study
this question, we overexpressed the active intracellular form of Notch-1 (NIC1) in BT474
sensitive cells, which we showed have low ERK1/2 activity. The data demonstrated that
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NIC1 overexpression was able to induce ERK1/2 phosphorylation, with no changes in
total ERK protein levels (Figure 2-4, left). Next, we asked the question: Is Notch
necessary to activate ERK? To address this question, we inhibited Notch-1 using an
siRNA in BT474 resistant cells and demonstrated that Notch-1 inhibition correlated with
a decrease in phosphorylated ERK, but no change in phosphorylated AKT (Figure 2-4,
right). Taken together, these data suggest that Notch-1 is both sufficient and necessary to
activate ERK1/2. Additionally, crosstalk between Notch-1 and ERK is present in a
biologically significant in vitro model of drug resistance.
Because ERK1/2 is only one of several MAP kinases, we asked whether Notch-1
was activating other MAP kinases or components of the MAPK signaling cascade. To
address this, we investigated the levels of phosphorylated p38 and JNK, two additional
MAP kinases, and MEK1/2, the activating kinase of ERK1/2 (Figure 2-5). In MCF-7,
SKBr3 and BT474 cells, Notch-1 inhibition had little to no effect on the phosphorylation
of p38, JNK or MEK1/2, demonstrating that Notch-1 does not activate the p38 and JNK
MAPK cascades nor does it activate MEK1/2.
Taken together, our results demonstrate a novel crosstalk between Notch-1 and
ERK1/2 in multiple breast cancer subtypes.

Our data show that Notch-1 is both

necessary and sufficient to activate ERK1/2. Additionally, our data demonstrated that
Notch-1 is not activating multiple MAPK signaling cascades or the activating kinase of
ERK, suggesting that Notch-1 is specifically activating ERK.
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Luminal A
ERα+ and/or PR+, Her2MCF-7
Luminal B
ERα+ and/or PR+, Her2+
BT474
–
–
+
Her2/Neu or Her2+
ERα , PR , Her2
SKBr3
Triple Negative
ERα–, PR–, Her2MDA-MB-231
Table 2-1. Breast cancer subtypes, molecular classification, and representative cell
line. Our study investigates ERK signaling in four cell lines, each one of which
represents a different molecular subtype of breast cancer.
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Figure 2-1. Notch-1 inhibition results in a decrease in ERK1/2 phosphorylation.
MCF-7 breast cancer cells were transfected with either scrambled control siRNA (SCBi)
or Notch-1 siRNA (Notch-1i) in the absence or presence of ICI, an ER antagonist,
Lapatinib, an EGFR and ErbB-2 inhibitor, or a combination of ICI plus Lapatinib.
Interestingly, Notch-1 inhibition resulted in a decrease in ERK phosphorylation
regardless of additional treatments. Notch-1 inhibition had little to no effect on AKT
phosphorylation.
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Figure 2-2. Notch-1 inhibition in five breast cancer cell lines. MCF-7, SKBr3, BT474
sensitive (BTHS), BT474 resistant (BTHR), and MDA-MB-231 cells were transfected
with scrambled control siRNA (SCBi) or Notch-1 siRNA (Notch-1i). ERK
phosphorylation was decreased in MCF-7, SKBr3 and BTHR cells. BTHS cells showed
low ERK activity that was relatively unaffected by Notch-1 inhibition. Notch-1 siRNA
had no effect on phosphorylated ERK in MDA-MB-231 cells.
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Figure 2-3. BT474 sensitive and resistant to trastuzumab cells have different levels
of phosphorylated AKT and ERK1/2. Trastuzumab resistant BT474 cells were
generated by treating cells with 10 µg/mL trastuzumab for 6 months in vitro.
Interestingly, resistant cells exhibited higher levels of phosphorylated AKT and ERK.
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Figure 2-4. Notch-1 is both necessary and sufficient to induce ERK1/2
phosphorylation. In BT474 HS cells, which exhibited low ERK activity, overexpression
of intracellular Notch-1 (NIC1) results in an induction of ERK1/2 phosphorylation. In
BT474 HR cells, inhibition of Notch-1 by siRNA results in a decrease in phosphorylated
ERK1/2 and no change in phosphorylated AKT.
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Figure 2-5. Inhibition of Notch-1 has no effect on phosphorylation of two other
MAP kinases, p38 and JNK, or on MEK1/2, a MAPK kinase. MCF-7, BTHS, BTHR
and SKBr3 cells were transfected with either scrambled control siRNA (SCBi) or Notch1 siRNA (Notch-1i). Notch-1 knockdown had little to no effect on the phosphorylation
of p38 and JNK, two other MAP kinases, or the upstream activating kinase of ERK1/2,
MEK1/2.
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Hypothesis
Based on the preliminary data, we proposed the following hypothesis: Notch-1
specifically activates ERK1/2 in multiple breast cancer cell lines by regulating a
MAPK phosphatase, a receptor tyrosine kinase, or MEK1/2.

Specific Aims
Aim 1. Determine whether Notch-1 activation of ERK1/2 is through inhibition of a
MAPK phosphatase or through activation of a receptor tyrosine kinase (Figure 2-6,
left).
Aim 1A. Crosstalks between intracellular signaling pathways are known to be
important in cell fate decisions, responses to extracellular stimuli and the development of
disease.

Notch and MAPK signaling pathways are both implicated in a variety of

cancers, including breast cancer, lung cancer and leukemia (Reedijk, Odorcic et al. 2005;
Chen, Jette et al. 2007; Dickson, Mulligan et al. 2007). However, while both signaling
pathways have been shown to play a role in cancer, any crosstalk mechanisms between
them remain unclear. Recently, a novel relationship between the Notch pathway and the
p38 MAPK pathway was identified in a skeletal muscle differentiation model (Kondoh,
Sunadome et al. 2007). The results from the study demonstrated that the Notch pathway
suppresses p38 MAPK signaling by specifically upregulating mitogen-activated protein
kinase phosphatase-1 (MKP-1), a negative regulator of MAP kinases. Therefore, in our
system, it was important to determine whether Notch-1 was regulating MKP expression.
To determine this, we measured both mRNA and protein expression levels in response to
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Notch-1 inhibition by siRNA. MKP mRNA expression levels were determined using
specific primers to MKP-1 through MKP-7. Changes in MKP-1 protein levels upon
Notch-1 inhibition were determined by Western blotting. Additionally, two different
siRNAs against MKP-1 were used alone and in combination with Notch-1 siRNA to
further examine whether Notch-1 was regulating MKP-1.
Aim 1B. The ERK1/2 signaling cascade is activated by growth factors acting
through receptor tyrosine kinases (RTKs) (May and Hill 2008). Of the many RTKs that
activate downstream signaling cascades, the EGFR/ErbB family of receptors binds
multiple ligands that are known to activate the ERK, including EGF, amphiregulin and
heregulin (Whyte, Bergin et al. 2009). Additionally, IGF-1 receptor and insulin receptors
are both known to activate the ERK1/2 MAPK cascade (Schlessinger 2003).

To

investigate whether Notch-1 activation of ERK was through an upstream receptor
tyrosine kinase, we performed a Human Phospho-Receptor Tyrosine Kinase (PhosphoRTK) array, which detects the relative phosphorylation levels of 42 different receptor
tyrosine kinases. Changes in the phosphorylation of RTKs were examined in MCF-7
cells upon Notch-1 inhibition and in BT474 sensitive cells upon NIC1 overexpression.

Aim 2. Establish whether Notch-1 activation of ERK1/2 is through regulation of
MEK1/2 (Figure 2-6, right).
MEK1/2 is the upstream activating kinase of ERK1/2. While our preliminary
data demonstrated that Notch-1 does not activate MEK1/2 (Figure 2-5), it was important
to determine whether Notch-1 might be regulating MEK in a manner besides
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phosphorylation. To address this, we used a specific MEK1/2 inhibitor, U0126, to inhibit
MEK both in the absence and presence of overexpressed NIC1 in BT474 sensitive cells.
To further elucidate the mechanism of Notch-1 and MEK crosstalk, we overexpressed
NIC1, inhibited MEK1/2, and used a proteasome inhibitor, MG132, to inhibit the
proteasomal degradation pathway.
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Figure 2-6. Notch-1 specifically activates ERK1/2 in multiple breast cancer cell lines
by regulating a MAPK phosphatase, a receptor tyrosine kinase, or MEK1/2. The
ERK1/2 MAPK cascade can be activated by various mechanisms. Our preliminary data
demonstrated that Notch-1 specifically activates ERK. We hypothesize that Notch-1
activates ERK through inhibition of MKP-1, a known inhibitor of ERK, or through
activation of an upstream receptor tyrosine kinase, such as IGF-1 receptor or insulin
receptor. Additionally, we hypothesize that Notch-1 activates ERK by upregulating
MEK1/2.

CHAPTER THREE
MATERIALS AND METHODS
Materials:
Cell Culture: Breast cancer cells described below are breast cancer cell lines (Table 3-1)
and most were purchased from American Type Culture Collection depository (ATCC,
Rockland, MD) unless otherwise stated and used in all in vitro experiments. The cells
were grown in the appropriate culture medium (described below) and cultured in a 37°C
sterile, 95% humidified incubator supplemented with 5% CO2.
MCF-7/Neo: MCF-7/Neo cells, denoted as MCF-7 henceforth, were kindly
provided by Dr. Mien-Chie Hung (University of Texas, M.D. Anderson Cancer Center,
Houston, TX). Cells were cultured in Roswell Park Memorial Institute medium (RPMI
1640, GIBCO) supplemented with 10% Fetal Bovine Serum (FBS, Cellgro), 1% nonessential amino acids (Cellgro), and 1% L-Glutamine (Cellgro).
SKBr3: SKBr3 cells are a human breast cancer cell line obtained from ATCC
(Rockville, MD, catalog #HTB-30). Cells are cultured in Improved Minimum Essential
Medium (IMEM, Cellgro) and supplemented as described previously.
BT474 HS and BT474 HR:

BT474 cells that are sensitive to Herceptin

(trastuzumab) are referred to as HS. These parental cells were obtained from the ATCC
(ATCC #HTB-20). BT474 cells that have acquired resistance to Herceptin are referred to
as HR cells. These cells were generated by Dr. Clodia Osipo from the parental HS cells
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by culturing cells in medium containing 10μg/mL Herceptin every three days for up to 6
months. Both HS and HR cells are cultured in Dulbecco’s Modification of Eagle’s
Medium (DMEM, Cellgro) and supplemented as described previously.
MDA-MB-231: MDA-MB-231 cells were kindly provided by Dr. Ruth Lupu
(Mayo Clinic, Rochester, MN).

Cells were cultured in Dulbecco’s Modification of

Eagle’s Medium (DMEM, Cellgro) and supplemented with 5% Fetal Bovine Serum
(FBS; Cellgro), 1% non-essential amino acids (Cellgro), and 1% L-Glutamine (Cellgro).
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Cell Line

Molecular Subtype

MCF-7

ERα+ and/or PR+, Her2-

SKBr3

ERα+ and/or PR+, Her2+

BT474

ERα- and/or PR-, Her2+

MDA-MB-231

ERα- and/or PR-, Her2-

Table 3-1. Molecular characterization of breast cancer subtypes. Our study examines
crosstalk between Notch-1 and ERK in four breast cancer cell lines, which each exhibit a
different molecular profile.
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Plasmid DNA
NIC1: The human Notch-1 intracellular domain (NIC1) expression plasmid was
kindly provided by Dr. Lucio Miele when he was the director of the breast cancer preclinical program at Loyola University Medical Center. NIC1 consists of the entire
intracellular Notch-1 sequence cloned into a pcDNA3.0 vector (Invitrogen).

Small Interfering RNA (siRNA)
Notch-1i: Notch-1 siRNA (Santa Cruz Biotechnology, Santa Cruz, CA, sc-36095)
was used to knocked down Notch-1 protein. Notch-1 siRNA was transfected using
Lipofectamine RNAi Max (Invitrogen) and Opti-MEM (Invitrogen). Scrambled siRNA
(Santa Cruz, sc-37007) was used as the control.
MKP-1i: MKP-1 siRNA (h) and MKP-1 siRNA (h2) (Santa Cruz, sc-35937 and
sc-44312) were used to knockdown MKP-1 protein. MKP-1 siRNA h and h2 were
transfected using Lipofectamine RNAi Max (Invitrogen) and Opti-MEM (Invitrogen).
Scrambled siRNA (Santa Cruz, sc-37007) was used as the control.

Antibodies
Experimental Antibodies: Phosphorylated-AKT1 (Thr308) and total AKT1 are
rabbit, monoclonal antibodies purchased from Cell Signaling Technology (Cell Signaling
Technology, Inc., Danvers, MA, #4056 and #4691).

Phosphorylated-p44/42 MAPK

(Thr202/Tyr204) and total p44/42 MAPK (ERK1/2) are rabbit, monoclonal antibodies
purchased from Cell Signaling (Cell Signaling, #4377 and #4695). Phosphorylated-JNK
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(Thr183/Tyr185) and total JNK antibodies are rabbit, monoclonal antibodies purchased
from Cell Signaling (Cell Signaling, #4668 and #9252).

Phosphorylated-MEK 1/2

(Ser217/Ser221) and total MEK 1/2 are rabbit, monoclonal antibodies purchased from
Cell Signaling (Cell Signaling, #9154 and #9122). MKP-1 (C-19) is a rabbit, polyclonal
antibody against an epitope near the C-terminus of MKP-1 of human origin (Santa Cruz,
sc-370). Notch-1 (C-20) is a rabbit, polyclonal antibody produced against an epitope in
the C-terminal region of Notch-1 (Santa Cruz, sc-6014-R). Phosphorylated-p38 MAPK
(Thr180/Tyr182) and total p38 MAPK are rabbit, monoclonal antibodies purchased from
Cell Signaling (Cell Signaling, #9211 and #9212).
Control Antibodies: Beta-actin is a rabbit, polyclonal antibody from Abcam
(Abcam, Cambridge, MA, ab8227). Glyceraldehyde Phosphate Dehydrogenase
(GAPDH) is a mouse, polyclonal antibody purchased from Sigma-Aldrich (SigmaAldrich, St. Louis, MO, G9545). These two antibodies were used to detect Actin or
GAPDH as loading controls for all Western blots.

Drug Treatments
U0126 (MEK 1/2 Inhibitor): U0126 was purchased from Cell Signaling (Cell
Signaling, #9903) and resuspended in 1.31 mL dimethyl sulfoxide (DMSO) (SigmaAldrich, 67-68-5). The working concentration used for the cell treatment was 10 µM.
MG132 (Z-Leu-Leu-Leu-al): MG132 is a proteasome inhibitor and was
purchased from Sigma (Sigma-Aldrich, 133407-82-6) and resuspended in DMSO
(Sigma-Aldrich). The working concentration used for the cell treatment was 10 µM.
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Experimental Methods:
Transfections
Notch-1 and MKP-1 siRNA
Principle: Notch-1 siRNA transfections were carried out using Lipofectamine
RNAiMAX (Invitrogen). Lipofectamine is a lipid-mediated transfection method that
uses specially designed cationic lipids to deliver the siRNA into the cell. The positively
charged head group of the cationic lipids bind the negatively charged phosphate
backbone of the nucleic acid forming the transfection complex, a liposomal structure with
a positive surface charge. The positive surface of the liposomes mediates interactions
between the transfection complex and the negatively charged cell membrane, facilitating
endocytosis of the complex. Once endocytosed, the nucleic acid can be delivered to the
nucleus for gene expression.
Method: All cells were transfected with Lipofectamine RNAiMAX. Cells were
plated at 75% confluency in the respective medium 24 hours prior to transfection.
Lipofectamine RNAiMAX was incubated with Opti-MEM to form the lipofectamine
mixture while Notch-1 siRNA, MKP-1 siRNA and/or control siRNA were incubated in
Opti-MEM for 5 minutes. Following the incubation, the lipofectamine mixture was
added to each of the siRNA mixtures to form the transfection complex. The transfection
complex was incubated for 20 minutes at room temperature. During the incubation, cells
were washed once with phosphate-buffered saline, pH 7.4 (PBS) and medium was then
replaced with full-serum-containing medium. Following the incubation, the complexed
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reagent was added to each well. The cells were grown for an additional 48 hours. Table
3-2 indicates the amounts of siRNA and transfection reagents used in each particular size
culture plate.
NIC1
Principle: NIC1 overexpression was carried out using FuGENE 6 (Roche) in
BT474 HS cells. FuGENE 6 is a proprietary blend of lipids and other components that
uses cationic polymers to deliver DNA into the cell. Negatively charged DNA binds the
polycation, forming a positively charged complex.

The complex interacts with the

negatively charged cell membrane, facilitating endocytosis of the complex.

Once

endocytosed, the DNA is delivered to the nucleus for gene expression.
Method: BT474 cells were transfected with NIC1 using the FuGENE 6 method.
Cells were plated at 75% confluency in the respective media 24 hours prior to
transfection.

FuGENE 6 was incubated with DMEM for 5 minutes, while either

pcDNA3.1 or NIC1 was incubated in DMEM. Following the incubation, the FuGENE 6
mixture was added to each of the DNA mixtures to form the transfection complexes. The
mixture was then incubated for 20 minutes at room temperature. During the incubation,
cells were washed once with PBS and medium was then replaced with full-serumcontaining medium. Following the incubation, the complexed reagent was added to each
well. The cells were grown for an additional 48 hours. Table 3-2 indicates the amounts
of DNA and transfection reagents used in each particular size culture plate.
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10 cm plate

Cells
Seeded
7.5 x 105

siRNA
(ug)
5

SFM
(uL)
750

Lipofectamine
(uL)
15

SFM
(uL)
750

Transfection
Medium (uL)
2000

6-well plate

2.5 x 105

2

100

4

100

500

10 cm
plate
6-well
plate

Cells
Seeded

DNA
(ug)

OPTIMEM (uL)

Fugene 6
(uL)

OPTIMEM (uL)

Transfection
Medium (uL)

7.5 x 105

6

750

15

750

2000

2.5 x 105

1

100

4

100

500

Table 3-2. Amounts of siRNA, DNA, media and transfection reagents used per cell
culture vessel for Lipofectamine RNAiMAX transfections.
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Western Blotting
Total Cell Lysates
Method: Cell monolayers were washed with PBS and placed on ice. Cells were
scraped and lysed in radioimmunoprecipiation assay (RIPA) buffer [0.1% sodium
dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 10 µM sodium fluoride, 10 µM
sodium orthovanadate, 200 µM PMSF and a protease inhibitor cocktail (Roche)].
Lysates were vortexted immediately for 15 seconds and then placed on ice for five
minutes. Samples were then sonicated 3 to 5 times for 5 seconds intervals on ice.
Protein concentration was determined using the bicinchoninic acid (BCA) colorimetric
assay (Pierce Chemicals, Rockford, IL).
Protein Concentration Determination
Principle: Multiple methods for total protein concentration determination are
available. The BCA-based protein assay (Pierce) was chosen because of its compatibility
with samples containing lysis buffer with detergents. The reaction produces a violet
color that is directly proportional to the amount of protein present and is measured
between x and x nm. A bovine serum albumin (BSA) standard curve is used to estimate
the amount of protein in each sample after the absorbance is determined.
Method: A range of bovine serum albumin (BSA) standards were from 0 µg/mL
to 10 µg/mL. 10 μL of each standard was pipetted in duplicate into a 96-well flat bottom
plate. 10 μL of each experimental cell extract was pipetted in triplicate into the same
plate. The working BCA reagent was prepared by diluting Reagent A to Reagent B at a
50:1 ratio and 200 μL were added to each well containing a standard or a sample. The
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plate was incubated at 37ºC for 30 minutes. The plate was then read on a microplate
reader (POLARstar OPTIMA Microplate Reader, BMG Labtech).

The protein

concentration was determined by comparison to the absorbance values of the BSA
standard curve. If the BSA standard curve displayed an R2 value of less than 0.98, the
protein determination was not considered valid and was repeated using freshly made
standards.
Immunoblotting:
Principle: Western blotting is used to detect specific proteins in a given sample of
cell extracts. SDS-PAGE, Gel electrophoresis separates denatured proteins based on
molecular weight, which are then transferred to a PVDF membrane. The membrane is
then probed with specific antibodies to detect the protein of interest. All Western blots
were carried out using the NuPageTM electrophoresis system (Invitrogen), which
includes pre-cast mini-gels (10 cm x 10 cm, 1.5 mm thickness) of either 4-12% or 7%
polyacrylamide.
Method: Samples from protein lysates were made at 10-30 μg in sample buffer
and 50 mM dithiothreitol (DTT) and were loaded into each lanes of the gel along with a
colored protein standard marker (SeeBlue, Invitrogen). The 4-12% polyacrylamide gels
were run at 200V for 70 minutes in MOPS running buffer (Invitrogen) and the 7% gels
were run at 150V for 60 minutes in Tris-Acetate running buffer. PVDF membranes (BioRad) were pre-soaked for 10 seconds in 100% methanol, followed by a wash in purified
water (Millipore-Q Water Purification System, MilliPore, Billerica, MA), and pre-soaked
in transfer buffer (Invitrogen) until use. Transfer sponges and 3 mm Whatman paper
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(Bio-Rad) are simultaneously equilibrated in transfer buffer. The transfer apparatus is
then assembled according to standard methods: three sponges, Whatman paper, gel,
PVDF membrane, Whatman paper, nine sponges. Transfers were run at 38V for 150
minutes in transfer buffer at room temperature. Following transfer, the apparatus was
disassembled and PVDF membranes were rinsed briefly in 1X TBST [Tris-buffered
Saline (TBS), 0.1% Tween-20, NP-40]. Membranes were then blocked in 5% BSA
(SeraCare) in TBST for 75 minutes. Following blocking, membranes were incubated
with primary antibodies at the optimal dilution in 5% BSA-TBST overnight on a rocker
at 4ºC. Alternatively, the membranes can be incubated with the primary antibodies for 1
hour at 37ºC, shaking every 20 minutes, followed by 1 hour at room temperature. Each
membrane was then washed three times in TBST for 10 minutes per wash.

The

membranes were then incubated with a horseradish peroxidase (HRP)-linked secondary
antibody at the optimal dilution in 5% BSA-TBST for 1 hour. The membranes were
washed three times in TBST for 10 minutes per wash. Following the final washes,
membranes were incubated with the ECL Western Blotting Substrate (Pierce) detection
solution (prepared at a ratio of 1:1 Detection Reagent 1 to Detection Reagent 2) for 5
minutes. Each membrane was then developed and pictures were taken using the FujiFilm
LAS-3000 imager (FujiFilm Imager). Alternatively, membranes were exposed to X-ray
film and developed in the dark room..
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Stripping the Membrane:
Principle: Stripping the membrane allows an antibody to be removed from a
PVDF membrane in order to reprobe the membrane for a different antibody. Typically, a
membrane was never stripped and reprobed more than three times.
Method: After developing, the membranes were briefly rinsed in 1X TBST. The
mild stripping buffer (Abcam) was added and the membrane was rocked for 10 minutes.
The stripping buffer was discarded and replaced with fresh stripping buffer and rocked
for another 10 minutes. Membranes were then washed twice in PBS for 10 minutes each
followed by two washes in TBST for 5 minutes per wash. Membranes were then blocked
in 5% BSA for one hour at room temperature and immunoblotting would continue.

Phospho-Receptor Tyrosine Kinase Array
Principle: The Human Phospho-Receptor Tyrosine Kinase (RTK) Array Kit
(R&D Systems, Minneapolis, MN, ARY001) is a screening tool designed to
simultaneously detect the relative tyrosine phosphorylation of 42 different receptor
tyrosine kinases (RTK). Since one of the aims of this project was to determine whether a
RTK was involved in Notch-1 activation of ERK1/2, the Phospho-RTK array eliminates
the need for numerous Western blot experiments, but works by the same principle as
Western blotting.
Method: Protein samples were prepared by the same method described in 3.2.2. a.
and b. The array membranes were blocked in Array Buffer 1 for 1 hour on a rocking
platform at room temperature. Cell lysates were then diluted in Array Buffer 1 and added
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to each membrane and incubated overnight at 4ºC on a rocking platform. Following
lysate incubation, the membranes were washed three times for 10 minutes each in 1X
Wash Buffer. The anti-phospho-tyrosine-HRP conjugate antibody was then added and
the membranes were incubated for 2 hours at room temperature on a rocking platform.
The membranes were washed again three times for 10 minutes each and
chemiluminescence reagents were added as described in 3.2.2.

Reverse Transcription, Quantitative Real Time PCR
RNA Extraction
Method: Totoal RNA was extracted using the Ambion RiboPure Kit (Ambion)
designed for rapid purification of high quality RNA from cultured cells.

Cells in

monolayer were rinsed with PBS and then scraped in 250-500 µL of TRI Reagent
(Ambion) and vortexed for 15 seconds. The homogenate was then incubated at room
temperature for 5 minutes. At this point, the homogenate can be frozen at -80ºC until
ready to be used for RNA extraction. 100 μL of bromo-chloropropane was added to the
homogenate and incubated for 5 minutes at room temperature. Following incubation, the
homogenate was centrifuged at 12,000 x g for 10 minutes at 4ºC. The top aqueous layer
was then transferred to a new centrifuge tube. 200 µL of ethanol was added to the
aqueous phase and was vortexed immediately. The samples were passed through the filter
cartridges once by centrifugation for 30 seconds at 12,000 x g at room temperature. The
filters were then washed twice with Wash Solution by centrifuging for 30 seconds at 12,
000 x g at room temperature. RNA was then eluted by adding 100 µL Elution Buffer and

centrifuging.
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RNA concentration was measured using the NanoDrop 3300

(ThermoScientific, Wilmington, DE). Reverse transcription (RT) of RNA to cDNA was
performed using the Fermentas reverse transcription kit (Fermentas, Glen Burnie, MD,
#K1612) according to the manufacturer’s instructions. The reverse transcription reaction
was then carried out in cycles at 95°C for 5 minutes.
Real Time PCR
1. Method: For each polymerase chain reaction (PCR) reaction, SYBR® Green
(Applied Biosystems, Carlsbad, CA) was used to prepare a master mix, which included
the desired forward and reverse primers and the sample cDNA. The primers used were:
MKP-1 (Forward- CTCCAAGGAGGATATGAAGCG and Reverse-CTCCAGCATCCTTGATGGAGTC),

MKP-2

(F-GTGGAAATCCTCCCTTTCCTCTAC

GATGTCGGCCTTGTGGTTGTCTTC),
GAATGCGG

and

MKP-3

and

R-

(F-GCCCAATCTGTTTGA-

R-CCTTTCGAAGTCAAGCAGCTGG),

MKP-4

(F-

CATCCTTCCCTGTCCAGATCCTG and R-CGGAGATGGGGATCTGCTTGTAG),
MKP-5

(F-CTCGAGCATG-CTACCTCAGTCTG

CCTCGATGAAC),

MKP-7

and

R-CTGGTGAGCTT-

(F-GGTGGCTTTGCTGAGTTCTCTC

CTCAGCCATTGGAGGCTTTTGC)

and

HPRT

and

R-

(F-ATGAACCAGG-

TTATGACCTTGAT and R-CCTGTTGACTG-GTCATTACAATA). The master mixes
and cDNA were pipetted into a 96-well plate and the PCR portion of the reaction was run
using the Applied Biosystems StepOnePlusTM Real-Time PCR System (Applied
Biosystems) under the conditions in Table 3-3.
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Stage 1

95ºC for 5 minutes

Stage 2

95ºC for 30 seconds for 50 cycles at an interval of 59ºC for 1 minute and
72ºC for 1 minute

Stage 3

95ºC for 15 seconds, 60ºC for 1 minute, 95ºC for 15 seconds, 60ºC for 15
seconds

Table 3-3. PCR stage specifications for a sample volume of 25 µL in each well.

CHAPTER FOUR
RESULTS
Specific Aim 1. Determine whether Notch-1 activation of ERK1/2 is through
inhibition of a MAPK phosphatase or activation of an upstream receptor tyrosine
kinase.
MAP kinase signaling pathways are activated and inactivated in a variety of
ways. Upstream, it has been shown that the ERK1/2 MAPK pathway is activated through
the activation of multiple receptor tyrosine kinases in response to growth factors or
cytokines. Downstream, ERK1/2 is inactivated by the dephosphorylation of its activating
tyrosine and threonine residues by several MKPs, including MKP-1 and -3. Both the
ERK1/2 and the Notch signaling pathways are implicated in a variety of cancers, but
direct crosstalk between the two pathways has yet to be demonstrated. Our preliminary
data demonstrated for the first time, to our knowledge, a novel crosstalk between Notch-1
and ERK1/2 in multiple subtypes of breast cancer. The goal of the first specific aim of
this thesis is to determine whether Notch-1 activation of ERK1/2 is mediated through
MKPs or receptor tyrosine kinases.
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Inhibition of Notch-1 by siRNA correlated with an increase in relative mRNA
transcript levels of MKP-1 in MCF-7, BT474 and MDA-MB-231 cell lines.
Our preliminary data demonstrated that the phosphorylation status of ERK1/2 was
decreased in response to Notch-1 knocked down by siRNA in multiple breast cancer cell
lines. In order to determine whether this effect was through a MAPK phosphatase, we
transfected MCF-7, BT474 sensitive, BT474 resistant, SKBr3, and MDA-MB-231 cells
with Notch-1 siRNA. The relative mRNA transcript levels of five MKPs (MKP-1, MKP2, MKP-3, MKP-4, MKP-7) in the five cell lines were determined by RT-real time PCR.
MCF-7 cells, in which ERK1/2 activity was greatly decreased upon Notch-1
inhibition, showed an increase in MKP-1, MKP-4 and MKP-7 transcript levels, while
MKP-2 and MKP-3 transcript levels were decreased (Figure 4-1, top). In BT474 cells, in
which ERK activity is low, Notch-1 inhibition correlated with an increase in MKP-1 and
MKP-3 transcript levels (Figure 4-1, middle left). MKP-2, MKP-4 and MKP-7 transcript
levels decreased slightly when Notch-1 was inhibited. In contrast, MKP transcript levels
remained relatively unchanged in BT474 resistant cells, with the exception of MKP-1,
which showed a nearly 2-fold increase (Figure 4-1, middle right). In SKBr3 cells,
transcript levels of MKPs-1, -2, -4 and -7 remained relatively unchanged upon Notch-1
inhibition, however MKP-3 transcript levels increased nearly 2-fold (Figure 4-1, bottom
left). Finally, in MDA-MB-231 cells, MKP-1 and -7 increased 3-fold, while MKP-4
transcript levels increased 5-fold, respectively (Figure 4-1, bottom right). Transcript
levels of MKPs-2 and -3 remained unchanged.
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Most importantly, the data showed that MKP-1 transcript levels were significantly
increased upon Notch-1 inhibition in three of the five cell lines (MCF-7, BT474 sensitive,
and BT474 resistant) (Figure 4-2).
These results demonstrated that Notch-1 inhibition resulted in a possible increase
in transcription of the MKP-1 gene. Taken together, the data suggested Notch-1 may
inhibit transcription of MKP-1. Since our focus on MKP-1 as an inhibitor of ERK1/2
requires its protein expression and activation, we decided to further investigate the effect
of Notch-1 inhibition on MKP-1 by measuring MKP-1 protein levels.
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Figure 4-1. MKPs 1 through 7 are differentially expressed in multiple breast cancer
cell lines. The relative mRNA transcript levels of five MKPs were examined using qRTPCR in five cell lines. The MKP transcript levels (gray bars) were normalized to the
scambled control (SCBi, black bars) of each cell line.
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Figure 4-2. MKP-1 mRNA transcript levels are significantly increased upon Notch1 inhibition by siRNA in multiple cell lines. MKP-1 mRNA transcripts were
upregulated when Notch-1 was inhibited by siRNA (N-1i) in comparison with scrambled
control siRNA (SCBi) in four of the five cell lines studied.
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Knock down of Notch-1 decreases MKP-1 protein in multiple cell lines and NIC1
increases MKP-1 protein in BT474 sensitive cells.
Although RT-PCR is a useful tool for studying changes in the expression of target
gene transcripts, it does not provide information about the changes in protein expression
of the gene. For this, we used Western blotting to probe for MKP-1 protein in MCF-7,
BT474, and SKBr3 cell lines. As shown by Figure 4-3, upon Notch-1 knocked down by
siRNA, MKP-1 protein levels decreased dramatically in MCF-7 cells and to a lesser
extent in SKBr3 and BT474 resistant cells. MKP-1 protein levels were low in BT474
sensitive cells, but decreased upon Notch-1 knocked down. To confirm this data, we
repeated the experiment in triplicate and immunoblotted for GAPDH as a protein loading
control.
Therefore, it appeared that Notch-1 knocked down inhibited MKP-1 protein
levels, despite an upregulation of MKP-1 mRNA transcript levels described previously
(Figure 4-2). This suggested that Notch-1 may upregulate, rather than inhibit, MKP-1 as
we initially hypothesized. To further examine whether Notch-1 was activating MKP-1,
we asked the question: Can overexpression of Notch-1 upregulate MKP-1 protein levels?
MKP-1 levels were much lower in BT474 sensitive cells than in the other cell lines.
Therefore, we chose to detect MKP-1 protein levels following NIC1 overexpression in
these cells.

As shown in Figure 4-4, our data showed that MKP-1 protein levels

increased when we overexpressed NIC1. This suggested that Notch-1 is sufficient to
induce MKP-1 protein expression. We repeated this experiment in triplicate, using beta-
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actin as a protein loading control. Figure 4-4 is representative of the three independent
experiments.

Dual inhibition of MKP-1 and Notch-1 does not rescue ERK1/2 phosphorylation.
To further investigate the crosstalk of Notch-1 and MKP-1 and the effects on
ERK1/2 phosphorylation, we transfected MCF-7 cells with Notch-1 siRNA, MKP-1
siRNA, or a combination of Notch-1 plus MKP-1 siRNA. Two different MKP-1 siRNAs
were used: MKP-1a and MKP-1b. As shown in Figure 4-5, Notch-1 siRNA resulted in a
decrease in phosphorylated ERK, with no change in total ERK protein that also coincided
with a decrease in MKP-1 protein. To determine the efficiency of MKP-1 knocked
down, we performed RT-PCR. The data showed that MKP-1ia was less effective at
knocking down MKP-1 than MKP-1ib (Figure 4-5, bottom right). Respectively, MKP-1
inhibition by siRNAb corresponded with the expected increase in phosphorylated ERK,
whereas MKP-1ia had no effect on ERK phosphorylation (Figure 4-5). MKP-1 protein
levels were decreased upon MKP-1 inhibition by both siRNAs.

Interestingly, the

combination of Notch-1i plus MKP-1ia or MKP-1ib did not rescue ERK phosphorylation
as was initially hypothesized.

From these results, we can conclude that Notch-1-

mediated activation of ERK1/2 does not require MKP-1.
Taken together, our results demonstrated that Notch-1 inhibition resulted in a
decrease in MKP-1 protein levels, while overexpression of NIC1 correlated with an
increase in MKP-1 protein levels. Additionally, dual inhibition of Notch-1 and MKP-1
was not able to rescue ERK1/2 phosphorylation. We concluded from these results that
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Notch-1 may be both necessary and sufficient for MKP-1 protein expression. This data
also suggested that Notch-1 activation of ERK1/2 is not mediated through regulation of
MKP-1, but is most likely downstream of MKP-1.
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Figure 4-3. Notch-1 inhibition by siRNA correlates with a downregualation of MKP1 protein levels. Notch-1 was inhibited in MCF-7, BTHS, BTHR and SKBr3 cells by
siRNA (Notch-1i). MKP-1 protein levels were decreased in all four cell lines upon
Notch-1 knockdown. GAPDH was used as a protein loading control.
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Figure 4-4. NIC1 overexpression induces MKP-1 protein expression. BT474
resistant cells were transfected with either control pcDNA3 or active intracellular Notch
(NIC1). Notch-1 overexpression correlated with an increase in MKP-1 protein levels.
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Figure 4-5. Dual inhibition of Notch-1 and MKP-1 by siRNA does not rescue
phopshorylation of ERK1/2. MCF-7 cells were transfected with scrambled control
(SCBi), Notch-1 (Notch-1i), or MKP-1 (MKP-1ia and MKP-1ib) siRNA. Confirming
previous results, Notch-1 inhibition resulted in a decrease in both ERK1/2
phosphorylation and MKP-1 protein levels. MKP-1ib was more efficient at inhibiting
MKP-1 than MKP-1ia, as can be seen from the qRT-PCR data (right). Accordingly,
inhibition of MKP-1 by MKP-1ib induced ERK phosphorylation. Interestingly, dual
inhibition of Notch-1 and MKP-1 did not rescue ERK1/2 phosphorylation.

65
Phosphorylation of VEGFR3 is decreased when Notch-1 is inhibited in MCF-7 cells.
The ERK1/2 signaling cascade is activated by growth factors and cytokines acting
through receptor tyrosine kinases (RTKs), including the ErbB family of receptors, IGF-1
receptor and insulin receptor. It was thus necessary to investigate whether Notch-1
activation of ERK1/2 was through activation of a receptor tyrosine kinase. To test this,
we performed a Human Phospho-Receptor Tyrosine Kinase (Phospho-RTK) array, which
detects the relative tyrosine phosphorylation of 42 different RTKs. To investigate this,
we transfected MCF-7 cells with Notch-1 siRNA and BT474 sensitive cells with NIC1.
As shown in Figure 4-6, MCF-7 cells, under vehicle conditions, have high
phosphorylation levels of IGF-1R, VEGR3 and moderate levels of EGFR and IR
phosphorylation (top). Interestingly, upon Notch-1 inhibition, the phosphorylation of
VEGFR3 is decreased, while the phosphorylation of IGF-1R, EGFR, and IR remain
unchanged (Figure 4-6, bottom). This data suggested that Notch-1 may be activating
VEGFR3 in MCF-7 cells.

BT474 sensitive cells have high levels of phosphorylated EGFR, ErbB-2 and ErbB-3.
In order to confirm whether VEGFR3 may be playing a role in Notch-1-mediated
activation of ERK, we overexpressed NIC1 in BT474 sensitive cells since we showed
previously that NIC1 was able to induce ERK1/2 phosphorylation in these cells. EGFR
and ErbB-3 are highly tyrosine phosphorylated in BT474 sensitive control cells
transfected with pcDNA3 (Figure 4-7, top left). The high phosphorylation levels of
ErbB-2 are consistent with the fact that BT474 cells contain a gene amplification for
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ErbB-2 thus resulting in overexpression of the ErbB-2 onco-protein.. When NIC1 is
overexpressed, the phosphorylation status of EGFR, ErbB-2 and ErbB-3 does not change.
Additionally, as a result of the high phosphorylation signal of the ErbB family of
receptors, the phosphorylation levels of other RTKs is diminished. Therefore, to examine
any changes in phosphorylation status of the other receptors in the array, we cut the ErbB
receptors from the array and subjected the membrane to a longer exposure time (Figure 47, right). However, even at a higher exposure, the phosphorylation levels of the other
receptors are generally low (Figure 4-7, top right). As a result of the MCF-7 PhosphoRTK array data, we denoted the IR, IGF-1R and VEGFR3 in the BT474 array. However,
there is no change in the phosphorylation levels of IR or IGF-1R upon NIC1
overexpression. Similarly, the phosphorylation of VEGFR3 did not change when NIC1
is overexpressed. This data demonstrates that active Notch-1 was unable to induce
phosphorylation of VEGFR3 in a reciprocal manner to the decrease in phosphorylation
when Notch-1 is inhibited by siRNA (Figure 4-6).
The Phospho-RTK array data from both MCF-7 and BT474 cells demonstrated
that, although VEGFR3 was inactivated by Notch-1 inhibition, no observable changes in
the phosphorylation status of any RTK were seen when NIC1 was overexpressed. Taken
together, our data suggest that Notch-1-mediated activation of ERK1/2 is most probably
not through the activation of a receptor tyrosine kinase.
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Figure 4-6. VEGFR3 phosphorylation is decreased when Notch-1 is inhibited.
MCF-7 cells transfected with scrambled control siRNA exhibited high phosphorylation of
IGF-1 receptor, VEGF3 receptor, EGFR, and insulin receptor. Notch-1 inhibition
correlated with a decrease in phosphorylation of VEGFR3, with no changes in IGF-1R,
EGFR, or IR.
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Figure 4-7. NIC1 overexpression has no effect on the phosphorylation levels of
receptor tyrosine kinases. BT474 sensitive cells were transfected with either control
pcDNA3 or NIC1. BTHS cells exhibit high levels of phosphorylated EGFR, ErbB-2
(Her2) and ErbB-3 (Her3), which are unaffected by NIC1 overexpression (left). Changes
in phosphorylation of other receptor tyrosine kinases were not detected at a higher
exposure (right).
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Specific Aim 2. Establish whether Notch-1 activation of ERK1/2 is through
regulation of MEK1/2.
MEK1/2 is the known activating kinase of ERK1/2 and has not been shown to
activate any other MAP kinases or other proteins of physiological relevance (Chen, Fujii
et al. 2001). MEK, like ERK, is activated by phosphorylation on threonine and tyrosine
residues. Previously, we demonstrated that Notch-1 inhibition had little to no effect on
the phosphorylation of MEK1/2. However, Notch has been shown to activate signaling
cascades through novel mechanisms, such as direct regulation of protein scaffolding that
regulates the activity of IKK (Shin 2007). Therefore, it was important to investigate
whether Notch-1 was activating ERK1/2 by regulating MEK1/2 through a novel
mechanism. The goal of the first specific aim of this thesis is to determine whether
Notch-1 activation of ERK1/2 is mediated through regulation of MEK1/2.

Overexpression of NIC1 is abrogated upon inhibition of MEK1/2 by U0126.
In order to determine whether Notch-1 activates ERK1/2 through upregulation of
MEK1/2, we overexpressed NIC1 in the presence or absence of a MEK1/2 inhibitor,
U0126. U0126 is a noncompetititve inhibitor of both MEK1 and 2, but has a higher
affinity for MEK1 (Duncia, Santella et al. 1998). Confirming our previous data, NIC1
overexpression in BT474 sensitive cells effectively induced ERK1/2 phosphorylation
(Figure 4-8) and had no effect on AKT phosphorylation (Figure 4-8, left).

Upon

treatment with the MEK1/2 inhibitor, ERK phosphorylation is greatly diminished
(U0126, pcDNA3 lanes). ERK1/2 phosphorylation is still inhibited in cells treated with

U0126 and overexpressing NIC1.
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Interestingly, in cells treated with U0126 and

transfected with NIC1, Notch-1 protein is no longer overexpressed and is, in fact,
decreased in comparison with the control cells. To confirm that Notch-1 was in fact
overexpressed in the U0126-treated cells, we performed RT-PCR. As can be seen from
the bottom right panel of Figure 4-7, Notch-1 transcript levels were greatly increased in
cells transfected with NIC1, including those treated with U0126. The data presented in
Figure 4-7 are representative of five independent experiments.

From this data, we

concluded that MEK1/2 is necessary for ERK1/2 activation.

MEK1/2 or ERK1/2 may play a role in Notch-1 stabilization.
To determine whether MEK1/2 was playing a role in the stabilization of Notch-1
protein, we overexpressed NIC1 in the presence or absence of U0126, MG132, a
proteasome inhibitor, or a combination of U0126 plus MG132. In cells transfected with
NIC1, Notch-1 protein is overexpressed compared to control cells (Figure 4-9).
Consistent with our previous data, Notch-1 protein is no longer overexpressed in cells
transfected with NIC1 and treated with U0126. Treatment with the proteasome inhibitor,
MG132, resulted in a dramatic increase in Notch-1 protein, which coincided with a
similarly dramatic increase in phosphorylated ERK1/2. Interestingly, dual treatment with
U0126 and MG132 did not result in a decrease of Notch-1 or phosphorylated ERK1/2
levels. Taken together with the previous figure (Figure 4-8), this data suggested that
Notch-1 was being rapidly degraded by the proteasome in cells treated with U0126 and
that inhibition of the proteasome could rescue Notch-1 protein and ERK1/2 activity.
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Additionally, the data suggested that Notch-1 protein stability might be critical for
ERK1/2 activation and that MEK1/2 or ERK1/2 may play a role in stabilizing Notch-1
protein.
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Figure 4-8. MEK 1/2 inhibition correlates with a decrease in Notch-1 expression in
cells overexpressing NIC1. BT474 sensitive cells were transfected with NIC1 in the
presence or absence of a MEK inhibitor, U0126. This figure shows two results from two
independent experiments that are representative of five independent experiments. NIC1
induced ERK phosphorylation and the MEK inhibitor was effective at preventing ERK
phosphorylation. However, when NIC1 was overexpressed with the MEK inhibitor,
Notch-1 overexpression was no longer detectable by Western blotting.
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Figure 4-9. Inhibition of the proteasome results in a large increase in Notch-1 and
phosphorylated ERK1/2. BT474 sensitive cells were transfected with either pcDNA3
or NIC1 in the presence of U0126, MG132, a proteasome inhibitor, or a combination of
U0126 plus MG132. NIC1 overexpression is diminished when cells were treated with
U0126, confirming previous data. Treatment of cells with the proteasome inhibitor,
regardless of NIC1 expression, dramatically induced Notch-1 protein levels, which
correlated with a large increase in phosphorylated ERK.

CHAPTER FIVE
DISCUSSION
The role of Notch-1 in ERK1/2 activation.
Because of several recent reports suggesting that the estrogen receptor inhibits
both Notch and ErbB-2, we became interested in understanding the complex crosstalk
mechanism that exists between these three pathways in breast cancer. We began this
current study by examining changes in protein expression and activation of multiple
signaling pathways when we inhibited ErbB-2, ER, and Notch-1 simultaneously in MCF7 breast cancer cells.

Interestingly, we found that inhibition of Notch-1 causes a

significant decrease in the phosphorylation of ERK1/2, regardless of additional inhibitors
to ER or ErbB-2 (Figure 2-1). Furthermore, we demonstrated that Notch-1 inhibition had
little to no effect on AKT phosphorylation, despite reports suggesting that Notch
signaling induces AKT activation in breast epithelial cells (Meurette, Stylianou et al.
2009). The same phenomenon was discovered in two additional breast cancer cell lines
to varying degrees (Figure 2-2).
Interestingly, in MDA-MB-231 cells, ERK1/2 signaling was not affected by
Notch-1 inhibition. MDA-MB-231 cells are known to have an activating K-ras mutation,
which could result in the constitutive activation of the ERK1/2 signaling cascade. In
such a case, Notch-1 may not be required for ERK activation since the pathway is already
hyperactive. Additionally, MDA-MB-231 cells are different from the other cell lines we
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examined in that they are negative for estrogen receptor, progesterone receptor and ErbB2 gene amplification. As a result, these cells may express downstream kinases or other
proteins responsible for ERK activation at different levels or not at all in comparison with
cells expressing ER and ErbB-2.
It is also important to note that in a cell line with low ERK1/2 activity, the BT474
sensitive to trastuzumab cells, we showed that Notch-1 inhibition had little to no effect on
the phosphorylation of ERK. However, previous members of our lab have demonstrated
that ERK1/2 phosphorylation can be effectively inhibited in these cells by treatment with
a Notch inhibitor, γ-secretase inhibitor (GSI), which inhibits the S3 cleavage of the Notch
receptors by the γ-secretase complex, thus preventing the release of the active Notch
intracellular domain (NIC). One explanation for this difference could be a disparity in
the confluency of cells when we performed the experiments since Notch signaling is
known to be dependent on cell-to-cell contact for activation. Regardless, these cells
provided a good model for studying whether Notch could induce ERK phosphorylation
because of their low ERK1/2 activity. Our data demonstrated that overexpression of
NIC1 effectively induced ERK1/2 phosphorylation in BT474 sensitive cells, indicating
that Notch-1 is sufficient to activate ERK.
Our results demonstrate, to our knowledge for the first time, that Notch-1
activates ERK1/2 in multiple breast cancer cell lines. The results clearly demonstrate that
ERK1/2 phosphorylation is significantly decreased upon Notch-1 inhibition and that
overexpression of active Notch-1 induces phosphorylation of ERK. The results suggest
that Notch-1 is both necessary and sufficient to activate ERK1/2 in multiple breast cancer
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subtypes. Previously, reports have described a cooperation between Notch and MAPK
signaling pathways in human breast carcinogenesis (Mittal, Subramanyam et al. 2009),
however, a direct link between Notch-1 and ERK1/2 specifically has not been identified
until now.

The role of Notch signaling in trastuzumab-resistant breast cancer.
Notch-1 is a potent breast oncogene that has been recently identified as a novel
biomarker of trastuzumab resistance (Mehta and Osipo 2009). The BT474 sensitive and
resistant cells we used in our experiments provide a biologically relevant in vitro model
for trastuzumab-resistant breast cancer. Our data demonstrated that both AKT and ERK
are more phosphorylated in trastuzumab resistant BT474 cells than in the sensitive cells
(Figure 2-3). Interestingly, other data from our lab showed that Notch-1 inhibition by a
GSI inhibited ERK and AKT activity, which coincided with a downgregulation of
proliferation and an induction of apoptosis, suggesting a role for Notch in activation of
these two pathways (Pandya, Meeke et al.). Taken together, our data seem to confirm
reports that suggest a critical role for Notch-1 possibly on ERK1/2 activation that could
be responsible for trastuzumab resistance.

Notch-1 differentially regulates MKP-1.
MAP kinase phosphatases (MKPs) have been implicated in chemoresistance in a
variety of cancers including lung and breast cancers.

In order to understand the

mechanism by which Notch-1 was activating ERK1/2 in the cell lines we examined, it
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was important to determine whether any MKPs were playing a role. A previous study
reported that Notch signaling suppresses p38 MAPK activity by inducing transcriptional
activation of MKP-1 in a myogenesis model (Kondoh, Sunadome et al. 2007).
Additionally, MKP-1 has been described as a factor for poor prognosis in breast cancer
(Rojo, Gonzalez-Navarrete et al. 2009). Our initial RT-PCR screen of the relative
changes in the mRNA transcript levels of five MKPs revealed that MKP-1 was
upregulated in four of the five cell lines examined (Figure 4-2). This data suggested that
Notch-1 was inhibitory to MKP-1 and that release of Notch-1 inhibition on MKP-1 could
be the cause of our observed downregulation of ERK phosphorylation.
Surprisingly, our Western blotting data indicated that, although Notch-1 may have
been activating MKP-1 transcription, Notch-1 inhibition actually correlated with a
decrease of MKP-1 protein levels (Figure 4-3). Conversely, overexpression of NIC1
resulted in an increase of MKP-1 protein (Figure 4-4). A recent report demonstrated that,
in T acute lymphoblastic leukemia (T-ALL) cells, Notch-3 regulates MKP-1 protein
levels in a similar manner to Notch-1 regulation of MKP-1 in our cells (Masiero,
Minuzzo et al.). Our data also demonstrated that dual inhibition of Notch-1 and MKP-1
could not rescue ERK phosphorylation, suggesting that Notch-1 activation of ERK may
be downstream of MKP-1 (Figure 4-5).

While the inhibitory effects of Notch-1

inhibition on MKP-1 protein levels could have implications in preventing the
proliferation and survival of breast cancer cells, we concluded that the Notch-1 activation
of ERK we observed was not due to regulation of MKP-1.
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Crosstalk between Notch-1 and VEGFR3.
Vascular endothelial growth factor receptor 3 (VEGFR3) overexpression has been
shown to promote proliferation, motility, survival and tumorigenicity in human breast
cancer cells (Shawber, Funahashi et al. 2007). Additionally, evidence has demonstrated
that Notch signaling directly induces VEGFR3 in blood endothelial cells during normal
vascular development (Shawber, Funahashi et al. 2007). In MCF-7 breast cancer cells,
our Phospho-RTK array data showed that the VEGF3 receptor was highly
phosphorylated in control MCF-7 cells and that Notch-1 inhibition correlated with a
pronounced decrease in the phosphorylation of the VEGF3 receptor (Figure 4-6).
Interestingly, previous studies have reported that VEGFR3 promotes angiogenesis and
lymphangiogenesis through activation of ERK1/2, JNK, and AKT pathways (Salameh,
Galvagni et al. 2005). This purported role of VEGFR3 in the activation of ERK1/2 could
provide an explanation for the high levels of ERK1/2 activity in MCF-7 cells.
Conversely, in BT474 sensitive cells, which exhibit low levels of ERK activity, VEGFR3
phosporylation was remarkably low, when normalized to the phosphorylated controls
(Figure 4-7). Taken together, our data confirmed a possible role for VEGFR3 in the
activation of ERK in breast cancer cells. The observed activity levels of VEGFR3 in
MCF-7 and BT474 cells, as measured by the Phospho-RTK array, may account for the
differential levels of ERK activity in the two cell lines.
However, while Notch-1 inhibition did result in a decrease in phosphorylated
VEGFR3 in MCF-7 cells, NIC1 overexpression in BT474 sensitive cells was unable to
induce VEGFR3 phosphorylation. This data suggested that Notch-1-mediated activation
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of ERK may not be through the VEGF3 receptor, but is possibly downstream of a
receptor tyrosine kinase.

MEK1/2 inhibition causes alterations in the proteasomal-mediated degradation of
Notch-1.
Two key pieces of data prompted us to hypothesize that MEK1/2 or ERK1/2 may
be playing a role in the protein stability of Notch-1.

First, not only was NIC1

overexpression no longer detected when MEK1/2 was inhibited by U0126, but also
Notch-1 protein levels were dramatically decreased under MEK inhibition (Figure 4-8).
Second, treatment with a proteasome inhibitor such as MG132 not only stabilized Notch1 protein levels to a high degree, but also significantly induced phosphorylation of
ERK1/2, even in the absence of active MEK (Figure 4-9). Recent data suggested a
critical role for MEK1 in the stabilization of MyoD, a protein that regulates myogenesis
in skeletal muscle cells (Jo, Cho et al.). The data demonstrated that degradation of MyoD
by the proteasome is inhibited by direct phosphorylation of MyoD by MEK1 (Jo, Cho et
al.).
Our data suggested that Notch-1 could have been rapidly degraded by the
proteasome upon MEK inhibition in BT474 sensitive cells. Additionally, inhibition of
the proteasome was able to rescue, and in fact, substantially increase Notch-1 protein
levels and ERK phosphorylation.

Interestingly, dual inhibition of MEK and the

proteasome had no additional effects on Notch-1 protein or ERK phosphorylation. We
speculated that it is possible that proteasome inhibition stabilizes Notch-1 to such a high
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extent that any MEK-mediated effects on Notch stabilization may be bypassed. We also
noticed that when NIC1 overexpression was undetectable when MEK was inhibited, ERK
phosphorylation was no longer induced by NIC1.

While the inhibition on ERK

phosphorylation could be a result of MEK inhibition, the data also suggested that Notch-1
stabilization could be critical for Notch-1-mediated activation of ERK. This would
suggest a positive feedback loop between MEK/ERK and Notch-1. Taken together, our
data suggested a role for MEK or ERK in the stabilization of the Notch-1 protein,
however, the exact mechanism remains unclear.

Working model for Notch-1 activation of ERK1/2.
In summary, the results from the current study clearly showed that Notch-1 is
both necessary and sufficient for the activation of ERK1/2 in multiple breast cancer
subtypes. Notch-1 upregulates MKP-1 protein and that Notch-1 regulation of ERK is
downstream of MKP-1. Additionally, Notch-1 inhibition causes a decrease in VEGFR3
phosphorylation and that VEGFR3 activity may be an explanation for the differential
activity of ERK among breast cancer cell lines. Furthermore, there may be a role for
MEK or ERK in the stabilization of the Notch-1 protein and that Notch-1 protein
stabilization may be important for its activation of ERK. Our working model for Notch-1
activation of ERK1/2 is presented in Figure 5-1.
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Future directions for the investigation of Notch-1 activation of ERK1/2.
Previous reports have demonstrated that ERK interacts with the death-associated
protein kinase (DAPK) and that DAPK promotes the cytoplasmic retention of ERK, thus
inhibiting ERK signaling (Chen, Wang et al. 2005). Therefore, an important future study
is to investigate whether Notch-1 activation of ERK is mediated through regulation of
DAPK. Additionally, MKP-3 has been shown to be a specific inhibitor of ERK1/2
(Groom, Sneddon et al. 1996) and exhibits tumor-suppressive effects in a pancreatic
cancer model (Furukawa, Sunamura et al. 2003). A thorough investigation of whether
Notch-1 regulates MKP-3 in order to activate ERK is thus an important future study.
ERK1/2 signaling has been implicated in a variety of cancers as a pro-proliferation and
pro-survival factor.

Future studies will be aimed at investigating whether Notch-1

regulates ERK activity in a variety of cancers in addition to breast cancer. Finally, it will
be critical to determine whether MEK, ERK or both regulate the stabilization of the
Notch-1 protein via direct or indirect phosphorylation in order to elucidate the
mechanism of this regulation.
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Figure 5-1. Working hypothesis of Notch-1 activation of ERK1/2. Our results also
demonstrated that MKP-1 is a negative regulator of ERK1/2 and that Notch-1 upregulates
MKP-1 protein expression. Additionally, our data showed that Notch-1 inhibition
correlates with a decrease in VEGFR3 phosphorylation and that VEGFR3 activity may be
an explanation for the different ERK phosphorylation levels in different breast cancer cell
lines. Finally, our data demonstrated that MEK, ERK or both stabilize Notch-1 protein
and may play a role in preventing degradation of Notch-1 by the proteasome. While, our
results clearly showed that Notch-1 activates ERK1/2 in multiple breast cancer subtypes,
future studies will investigate the exact mechanism of this novel crosstalk.
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